Research comparison
Semaglutide vs Tirzepatide
Side-by-side comparison of research status, mechanisms, pharmacokinetics, and administration routes.
Research Status
Approved
Approved
Half-Life
~1 week (allows once-weekly dosing)
~5 days (once-weekly dosing)
Mol. Weight
—
—
Admin Routes
subcutaneous, oral
subcutaneous
Categories
GLP-1 & Metabolic Hormones, Fat Loss & Metabolic, Cardiovascular
GLP-1 & Metabolic Hormones, Fat Loss & Metabolic
Interaction
caution
Both are GLP-1 receptor agonists (tirzepatide also hits GIP-R); stacking them is redundant and likely amplifies GI side effects including nausea, vomiting, and gastroparesis risk without meaningful additional benefit.
well-documented
Mechanism
Pharmacokinetics
Research Findings
Safety
Related comparisons